Please login to the form below

Not currently logged in
Email:
Password:

Breyanzi

This page shows the latest Breyanzi news and features for those working in and with pharma, biotech and healthcare.

FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies

FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies

T-cell malignancies have been seen in patients treated with several approved products in the class, including Bristol Myers Squibb’s (BMS) Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel), Johnson &Johnson

Latest news

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
nzyme

The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...